April 22, 2026 2:23 pm

Latest Posts

New Hope for Severe Crohn’s: Breakthrough Drug Targets Scarring

Agomab Therapeutics has launched a groundbreaking clinical trial for ontunisertib, a drug specifically targeting fibrostenosing Crohn’s disease—the severe, scarring form that has limited treatment options. This represents the first targeted therapy designed to address the root cause of intestinal scarring rather than just managing symptoms.

The FMT Study That Didn’t Work: What It Teaches Us About Crohn’s

A recent study tested fecal microbiota transplantation (FMT) for Crohn’s disease with disappointing results—but what can we learn from this setback? While FMT didn’t improve remission rates in 8 weeks, the research offers valuable insights for future treatments and reminds us that progress in IBD research often comes through understanding what doesn’t work.

You Missed

Breakthrough EV-RNA Research Could Transform IBD Diagnosis and Treatment

Breakthrough EV-RNA Research Could Transform IBD Diagnosis and Treatment

April 14, 2026
Acute Severe Ulcerative Colitis in Older Adults: Understanding the Heightened Risks and What It Means for You

Acute Severe Ulcerative Colitis in Older Adults: Understanding the Heightened Risks and What It Means for You

April 13, 2026
This Week in IBD: Your Weekly Roundup for April 6-12, 2026

This Week in IBD: Your Weekly Roundup for April 6-12, 2026

April 12, 2026
Vitamin D Shows Promise for Resetting Immune Response in IBD: What This Could Mean for Your Treatment

Vitamin D Shows Promise for Resetting Immune Response in IBD: What This Could Mean for Your Treatment

April 12, 2026